Literature DB >> 23408179

miR-155 Down Regulation by LNA Inhibitor can Reduce Cell Growth and Proliferation in PC12 Cell Line.

Fatemeh Kouhkan1, Shaban Alizadeh, Saeid Kaviani, Masoud Soleimani, Ali Akbar Pourfathollah, Naser Amirizadeh, Saeid Abroun, Mehrdad Noruzinia, Shahin Mohamadi.   

Abstract

MicroRNAs (miRNAs) are a class of small non coding regulatory RNAs that have key functions in multiple cell processes. Deregulation of these tiny miRNAs is involved in various human diseases. MiR-155 is one of the multifunctional miRNA that its over-expression has been found to be associated with different kinds of cancer such as leukemia, breast and colon cancers. It is thought that deregulation and over-expression of this microRNA may be associated with PC12 cell proliferation. So, the aim of this study was to investigate the role of miR-155 expression on PC12 cell growth. For this reason, PC12 cells were cultured and transfected by 3 different concentration (25, 50 and 75 nmol) of either LNA anti-miR-155 or scramble antisense in 24-well plate. Then, total RNA was extracted from transfected cells. miRNA cDNAs were synthesized from isolated total RNA. In the second step, miR-155 expression level was analyzed using the quantitative real-time polymerase chain reaction (QRT-PCR). MTT test was performed to evaluate cell viability. In the next step, apoptosis assay was assessed to investigate anti miR-155 effect on PC12 cells death. Obtained results were analyzed with t-test. MTT test revealed that cell viability of transfected cells with 75 nM of anti-miR- 155 to be reduced by half of the control and scramble groups (0.5 vs. 0.97 and 0.94). Our data suggest that miR-155 over-expression is associated with PC12 cell growth. So, miR-155 down regulation by anti-miR-155 could open up new ways to restrain brain tumor growth, as anti-miR-155 causes PC12 cells to repress.

Entities:  

Keywords:  Apoptosis; MTT test; PC12 cells; miR-155

Year:  2011        PMID: 23408179      PMCID: PMC3558181     

Source DB:  PubMed          Journal:  Avicenna J Med Biotechnol        ISSN: 2008-2835


Introduction

microRNAs are tiny regulatory molecules that have important role in various biological processes such as proliferation, cell death, differentiation and metabolism (1–5). Misregulation of these molecules is correlated with different pathogenic situations including tumorogenesis (6). In cancer, miRNAs act as oncogenes or tumor suppressors. Over expression of oncogenic miRNAs (oncomiRs) can down regulate tumor suppressors and/or other genes involved in cell differentiation, thus leading to tumor formation by stimulating proliferation, angiogenesis, and invasion. Similarly, tumor suppressor miRNAs can down regulate different proteins with oncogenic activity (7–11). Recent studies point out that miR-155 frequently up regulates in various cancers, so it is considered as oncomiR (12). Brain tumors are created by abnormal proliferation of cells that normally exist in the brain such as neurons or spread from cancers primarily located in other organs. However, any brain tumor is inherently dangerous and life-threatening. So, there is considerable interest in identifying more effective therapeutic strategies for treatment of brain tumors (10). Anti-miRs are chemically modified, single stranded nucleic acids designed to specifically bind to and inhibit endogenous microRNA (miRNA) molecules. Thus, they are miRNA Inhibitors. In general, anti-miRs have many benefits in cancer treatment including efficiency, precision, versatility, speed and cost-effectiveness (13–19). Therefore in this study, we investigated the anti miR-155 effect on repression of PC12 tumor cell growth and proliferation. The PC12 is a cell line that is established from rat pheochromocytoma. PC12 cells divide and resemble sympathetic neurons, when grown in Nerve Growth Factor (NGF) containing media. Thus, the PC12 cell line is used as a model system for neuronal cells.

Materials and Methods

Cell cultures

Pc12 cell line was maintained in RPMI 1640 supplemented with 10% Fetal Bovine Serum (FBS) and 50 mg/ml penicillin/ strep-tomycin in a humidified incubator containing 5% CO2 at 37 °C. Cells were fed three times a week and passaged every 7 days.

Oligonucleotide sequences

5' fluorescent antisenses: anti-155 (CCTA TCACGATTAGCATT, EXIQON, product no:410078-04);5'fluorescent scramble siRNA (GTGTAACACGTCTATACGCCCA,EXIQON product no:199004-08). QRT-PCR primers: miR-155 forward primer (5'-TTAATGCTA ATCGTGATAGG-3'); U6 forward primer (5'- CTCGCTTCGGCAGCACACATATAC-3'),U6 reverse primer (5'-ACGCTTCACGAATT TGC GTGTC-3').

Transfection and MTT experiments

Twenty four hr before transfection 5×105 PC12 cells were seeded per well in 24 well plate and allowed to grow overnight. The cells were then transfected with three different concentration of anti-155 (25 nM, 50 nM and 75 nM, respectively) and highest concentration of scramble siRNA(75 nM) using lipo-fectamine 2000 (Invitrogene) according to the manufacture's protocol. Scramble siRNA dose not target any known miRNA in trans-criptome. These anti-miRs were purchased from Exiqon Company. The day after transfection, medium was replaced with fresh RPMI containing 10% FBS. Cultures were incubated for the next day at 37 °C. Then, the cells were treated with MTT solution (5 mg/ml) for 4 hr. Thereafter, Dimethyl Sulfoxide (DMSO) were added to each well and absorption at wavelength of 540 nm measured by a spectrophotometer.

miRNA extraction and real-time

Total RNAs were extracted from transfected cells using biozol reagent (Bioneer Company). miRNAs cDNA were synthesized by Stratagene kit according to manufacturer's protocol. Thereafter QRT-PCR of miR-155 was performed with general reverse primer of Stratagene kit and specific forward primer for miR-155. The miR-155 expression was normalized to an endogenouse control U6. Relative expression was computed with relative standard curves for miR-155 and U6.

Apoptosis assay

Apoptosis assay was carried out in duplicate experiments using caspase-3 colorimetric activity assay kit (Millipore Company). Briefly, anti miR-155 transfections were performed as mentioned above. After 72 hr of transfection,0.5×106 cells were suspended in 100µl of chilled 1X cell lysis buffer and incubated on ice for 10 min and then centrifuged for 5 min at 10000 g. Assay mixtures were prepared in a 96-well plate. Twenty µl of 5X assay buffer and 10 µl of caspase-3 substrate (Ac-DEVD-pNA) were added to each test samples. Test samples were incubated for 2 hr at 37 °C. Then absorbance at 405 nm was measured with a microtiter plate reader. Fold increase in caspase-3 activity was calculated by comparing the OD reading from the induced apoptotic test samples with the level of the un-induced control.

Statistical analysis

The t-test was performed to investigate the differences in the obtained results of the three groups in the MTT and apoptosis analysis. Probability of 5% was assumed statistically significant.

Results

PC12 cells were divided in 3 groups: control group, scramble group that was transfected by 75 nM of scramble antisense and test group that was transfected by 25 nM, 50 nM and 75 nM of anti miR-155. Transfection efficiency was determined using inverted fluorescence microscope. Transfected cells with at least 70% efficiency were selected for further analysis. QRT-PCR analyses revealed that miR-155 expression was decreased in cells transected by different concentrations of anti-miR compared to control group (3 fold decrease for 25 nM, 5 fold decrease for 50 nM and 6.75 fold decrease for 75 nM concentrations of anti miR-155). No statically important differences were observed between miR-155 expression in control and scramble groups (Figure 1).
Figure 1

Relative Q-PCR of miR-155 level in PC12 cell line. (1) Control PC12 cells. (2) PC12 cells transfected by 75 nM of scramble. (3) PC12 cells transfected by 25 nM of anti miR-155(4) PC12 cells transfected by 50 nM of anti miR-155(5) PC12 cells transfected by 75 nM of anti miR-155

Relative Q-PCR of miR-155 level in PC12 cell line. (1) Control PC12 cells. (2) PC12 cells transfected by 75 nM of scramble. (3) PC12 cells transfected by 25 nM of anti miR-155(4) PC12 cells transfected by 50 nM of anti miR-155(5) PC12 cells transfected by 75 nM of anti miR-155 In the next step, cytotoxic effect of different concentration of anti miR-155 and scramble antisense were evaluated 48 hr after transfection by microscopy, trypan blue staining and MTT test. Optical densities at 540 nm were obtained for 3 groups: 0.971 for control group 0.962 for scramble group and 0.796, 0.659 and 0.561, respectively for 25 nM, 50 nM and 75 nM concentrations of anti miR-155 (Figure 2).
Figure 2

MTT assay on control, scramble and test groups

MTT assay on control, scramble and test groups These results demonstrated that optical density and therefore cell viability was similar in control and scramble groups (t = 3.60, p = 0.06). However, there were significant differences between optical density and cell viability in anti miR-155 group compared to control groups (t = 55.9723, p = 0.0003, t = 68.44, p = 0.0002, t = 182.01, p = 0.0001, respectively for 25 nM, 50 nM and 75 nM concentrations of anti miR-155). Optical density and cell viability gradually decrease with increase in anti miR-155 concentration (0.796, 0.659 and 0.561 respectively). At 75 nM concentration of anti miR-155, optical density and cell viability were half of these parameters in control group. These data indicated that higher concentration of anti miR-155 had higher toxicity effect on PC12 cells and could decrease the cell viability and proliferation. In the next step, we tried to identify the toxic effect of anti miR-155 (due to its effect on apoptosis pathway). For this reason, caspase-3 activity was calculated in 3 groups by caspase-3 colorimetric activity assay kit. Optical densities at 405 nm were 0.099 for control group, 0.097 for scramble group and 0.117 and 0.119 for anti-miR-155 group, that respectively was transfected by 50 and 75 nM of anti-miR (Figure 3). According to these data, there were no statically differences between optical density and caspase-3 activity between control and scramble groups (t = 0.44, p = 0.70) and control and anti miR-155 groups (t = 1.34, p = 0.31 for 50 nM concentration of anti miR-155 and t = 1.32, p = 0.31 for 75 nM concentration of anti miR-155).
Figure 3

Effect of anti miR-155 on caspase-3 activity in control, scramble and test groups

Effect of anti miR-155 on caspase-3 activity in control, scramble and test groups

Discussion

microRNAs are a class of small non-coding single-stranded RNA molecules that participate in control of gene expression by repression protein translation or by destabilizing target mRNA via cleavage or deadenylation. Any changes in the expression level of specific miRNAs are associated with multiple human diseases including diabetes, heart diseases, neurological diseases, hypertension and cancer (20–22). Cancer is the multistep process caused by uncontrolled cell proliferation. Recent studies demonstrate that some miRNAs are considered as oncogenes or tumor suppressors and have important roles in tumor initiation, progression and metastasis (11, 22). In 2002 for the first times, Calin and his partners indicated that down regulation of miR-15 and miR-16 was linked with chronic lymphocytic leukemia. So, these genes are thought to function as tumor suppressor (23–24). On the other hand, some miRNAs act as oncogenes and are called oncomirs. Up regulation of these miRNAs could cause the tumor progression (25). miR-155 can be regarded as an oncomir whose expression is increased in different cancers including T cell lymphoma, leukemia, breast, thyroid and colon cancers (26–29). So, in this study, we utilized anti-miR-155 for repression of PC12 growth and proliferation. Transfection of PC12 cells with either anti miR-155 or scramble were done successfully by at least 70% efficiency. MTT test was performed and results indicated that although 25 nM and 50 nM of anti miR-155 have toxic effect, on PC12 cells, 75 nM of anti miR-155 could repress tumor cell proliferation strongly (half of the control group). On the other hand, apoptosis analysis demonstrated that caspase-3 activity was similar in control group (0.099), scramble group (0.097) and anti miR group (0.117 for 50 nM and 0.119 for 75 nM of anti-155). Thus, anti miR-155 did not influence PC12 apoptosis. Consequently, anti miR-155 could decrease PC12 cells development, but could not induce apoptosis in these cells. Previous studies have indicated that a number of genes that are regulated by miR-155 are involved in biological processes such as immune response (for instance Pu1 and SHIP1), inflammation (BACH1 and ZIC3) and cell growth/survival (TP53NP1, FOXO3 and GSK3β) (12, 26, 30–32)333435. Thus, miR-155 could promote cancer development and proliferation by targeting genes that control cell cycle arrest such as tumor protein 53-induced nuclear protein 1(TP53INP1), (25, 31). However, there is little information from direct targets or exact pathways through which miR-155 signals function to promote the PC12 tumor cell development and proliferation.

Conclusion

In summary, our data for the first time indicated that down regulation of miR-155 by anti-miRNA, that has sequence complementary to mature miR-155, may be a useful approach for inactivating this microRNA in brain tumors and cause slow tumor growth, development and proliferation. Meanwhile further investigation would be necessary for identification of the exact mechanism through which anti miR-155 influence the PC12 tumor cells growth and proliferation.
  29 in total

1.  High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma.

Authors:  Markus Metzler; Monika Wilda; Kerstin Busch; Susanne Viehmann; Arndt Borkhardt
Journal:  Genes Chromosomes Cancer       Date:  2004-02       Impact factor: 5.006

Review 2.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

Review 3.  siRNAs: applications in functional genomics and potential as therapeutics.

Authors:  Yair Dorsett; Thomas Tuschl
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

4.  Knockdown of survivin gene expression by RNAi induces apoptosis in human hepatocellular carcinoma cell line SMMC-7721.

Authors:  Sheng-Quan Cheng; Wen-Liang Wang; Wei Yan; Qing-Long Li; Li Wang; Wen-Yong Wang
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

Review 5.  How microRNAs control cell division, differentiation and death.

Authors:  Eric A Miska
Journal:  Curr Opin Genet Dev       Date:  2005-10       Impact factor: 5.578

Review 6.  MicroRNA signatures in human cancers.

Authors:  George A Calin; Carlo M Croce
Journal:  Nat Rev Cancer       Date:  2006-11       Impact factor: 60.716

7.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.

Authors:  George Adrian Calin; Calin Dan Dumitru; Masayoshi Shimizu; Roberta Bichi; Simona Zupo; Evan Noch; Hansjuerg Aldler; Sashi Rattan; Michael Keating; Kanti Rai; Laura Rassenti; Thomas Kipps; Massimo Negrini; Florencia Bullrich; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-14       Impact factor: 11.205

8.  miR-15 and miR-16 induce apoptosis by targeting BCL2.

Authors:  Amelia Cimmino; George Adrian Calin; Muller Fabbri; Marilena V Iorio; Manuela Ferracin; Masayoshi Shimizu; Sylwia E Wojcik; Rami I Aqeilan; Simona Zupo; Mariella Dono; Laura Rassenti; Hansjuerg Alder; Stefano Volinia; Chang-Gong Liu; Thomas J Kipps; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-15       Impact factor: 11.205

9.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

Review 10.  MicroRNAs and cancer.

Authors:  Michael T McManus
Journal:  Semin Cancer Biol       Date:  2003-08       Impact factor: 15.707

View more
  8 in total

1.  MicroRNA-146 protects A549 and H1975 cells from LPS-induced apoptosis and inflammation injury.

Authors:  Qiang Wang; Dagang Li; Yuquan Han; Xiaoqian Ding; Tao Xu; Bingjian Tang
Journal:  J Biosci       Date:  2017-12       Impact factor: 1.826

Review 2.  Roles of the miR-155 in Neuroinflammation and Neurological Disorders: A Potent Biological and Therapeutic Target.

Authors:  Seyed Hamidreza Rastegar-Moghaddam; Alireza Ebrahimzadeh-Bideskan; Sara Shahba; Amir Mohammad Malvandi; Abbas Mohammadipour
Journal:  Cell Mol Neurobiol       Date:  2022-02-02       Impact factor: 5.046

3.  The Effect of miR-210 Up-regulation on Proliferation and Survival of Mouse Bone Marrow Derived Mesenchymal Stem Cell.

Authors:  Neda Minayi; Shaban Alizadeh; Hosein Dargahi; Masoud Soleimani; Zahra Kashani Khatib; Behnoosh Tayebi; Mozhde Mohammadian; Sadegh Alijani; Farshid Karami
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2014

4.  Mir-55 inhibition can reduce cell proliferation and induce apoptosis in Jurkat (Acute T cell Leukemia) cell line.

Authors:  Sh Alizadeh; S Kaviani; M Soleimani; S Abroun; Z Kashani-Khatib; A Asgharzadeh; H Dargahi; R Mousavi
Journal:  Iran J Ped Hematol Oncol       Date:  2014-12-10

5.  Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer.

Authors:  Qing Geng; Tao Fan; Boyou Zhang; Wei Wang; Yao Xu; Hao Hu
Journal:  Respir Res       Date:  2014-11-25

Review 6.  The Role of MicroRNAs in Myeloproliferative Neoplasia.

Authors:  Shaban Alizadeh; Seyed Ghader Azizi; Masoud Soleimani; Yadollah Farshi; Zahra Kashani Khatib
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2016-07-01

7.  Lovastatin Reduces Stemness via Epigenetic Reprograming of BMP2 and GATA2 in Human Endometrium and Endometriosis.

Authors:  Mahdieh Taghizadeh; Mehrdad Noruzinia
Journal:  Cell J       Date:  2016-12-21       Impact factor: 2.479

8.  The impact of Mir-9 regulation in normal and malignant hematopoiesis.

Authors:  Abbas Khosravi; Shaban Alizadeh; Arsalan Jalili; Reza Shirzad; Najmaldin Saki
Journal:  Oncol Rev       Date:  2018-03-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.